[Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer].
OBJECTIVE
To analyze loss of heterozygosity (LOH), loss of expression and somatic mutations of BRCA1, BRCA2 and p53 genes in sporadic epithelial ovarian cancer samples.


METHODS
Original paper.


METHODS
Oncogynecologic center, Clinic of Obstetrics and gynecology, First Faculty of Medicine, Charles University in Prague and General Teaching Hospital, Prague.


METHODS
We used genomic DNA and total RNA from peripheral blood and fresh frozen tumor as a template for LOH, loss-of-expression and mutation analyses.


RESULTS
LOH in at least one region was found in 60% of tumors. Majority of these alterations occurred not solely, but in conjunction with other region deletions.


CONCLUSIONS
Our study confirms high frequency of somatic alteration of BRCA1, BRCA2 and p53 genes in sporadic epithelial ovarian cancer.
Zikán
M
M
Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha. michal.zikan@lf1.cuni.cz
Pohlreich
P
P
Freitag
P
P
Janousek
M
M
Pavlista
D
D
Fischerová
D
D
Jancárková
N
N
Sláma
J
J
Pinkavová
I
I
Cibula
D
D
D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D002277:Carcinoma / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D020868:Gene Silencing; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D019656:Loss of Heterozygosity; D009154:Mutation; D010051:Ovarian Neoplasms / Q000235:genetics*
D019313:BRCA1 Protein; D024682:BRCA2 Protein